SCHEMBL427152

SCHEMBL427152

CN(C(=O)n1cnc(-c2ccc(O)cc2)c1)c1ccc(F)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 2/20 0.42
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
ATM Q13315 1/20 0.40
TP53 P04637 2/20 0.39
LMNA P02545 1/20 0.39
SCN4A P35499 1/20 0.38
MLNR O43193 1/20 0.37
GPBAR1 Q8TDU6 1/20 0.37
CES2 O00748 1/20 0.36
APP P05067 2/20 0.36
ESR1 P03372 2/20 0.36
ESR2 Q92731 1/20 0.36
USP2 O75604 1/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP1A2 P05177 1/20 0.36
GLA P06280 1/20 0.36
CYP3A4 P08684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL426706 0.89 GPBAR1 (0.46) FAAHMEN1KMT2ANPC1RAB9A
SCHEMBL425550 0.88 FAAH (0.51) FAAHMEN1KMT2ATP53LMNA
SCHEMBL426698 0.87 FAAH (0.52) FAAHMEN1KMT2ANPC1RAB9A
SCHEMBL425556 0.86 L3MBTL1 (0.43) FAAHTP53LMNASCN4A
SCHEMBL427489 0.80 FAAH (0.40) FAAHTP53LMNAMLNRGPBAR1
SCHEMBL427476 0.79 FAAH (0.57) FAAHKMT2ARAB9ATP53LMNA
SCHEMBL425371 0.78 FAAH (0.60) FAAHKMT2ANPC1RAB9ATP53
SCHEMBL425420 0.76 FAAH (0.52) FAAHCES2FYN
SCHEMBL426994 0.75 FAAH (0.51) FAAHMEN1KMT2ARAB9ATP53
SCHEMBL425400 0.75 FAAH (0.54) FAAHLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
WO-2010074588-A2 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2010-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS FAAH, FAAH2, ASAH1 FAAH 1/4885MEN1 2893/4885KMT2A 2067/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.